Yaral Pharma Launches in the US

Yaral Pharma Launches in the US




Yaral Pharma Launches in the US

US Subsidiary of IBSA to Commercialize Generic Portfolio

PARSIPPANY, N.J.–(BUSINESS WIRE)–Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable, authorized generics (AG) and complex generic medicines to enhance healthcare outcomes.

Led by a team of industry veterans, Yaral Pharma will begin commercializing the first product from IBSA’s corporate pipeline of authorized generics in January 2023. Yaral Pharma’s current portfolio includes products across a range of therapeutic areas, including pain and endocrinology. It plans to rapidly expand its product line and therapeutic areas of focus through outside opportunities and external partnerships.

IBSA is particularly known for its manufacturing expertise and decades-long track record of product quality and supply continuity. The Company continues to build a wide-ranging portfolio of products across brands and generics in ten core therapeutic areas including pain and inflammation and endocrinology and manufactures novel delivery systems including soft gel capsules and patch technology. IBSA is also recognized as one of the largest players worldwide in the area of reproductive medicine and one of the world’s leaders in hyaluronic acid-based products.

Our parent company IBSA is recognized as a world leader in the development of innovative technologies and products that improve the health and wellness of people,” said Stephen Beckman, CEO, Yaral Pharma. “We look forward to drawing on these strengths and providing our customers with high-quality products, continuity of supply, and exceptional levels of service.”

For the latest updates on Yaral Pharma, please visit www.yaral-pharma.com or connect with us on LinkedIn.

About Authorized Generics

According to the U.S. Food and Drug Administration, the term “authorized generic” drug is most commonly used to describe an approved brand name drug that is marketed without the brand name on its label. Other than the fact that it does not have the brand name on its label, it is the exact same drug product as the branded product. The product the patient receives is identical to the branded product, contains the same active and inactive ingredients, and is manufactured using the same process at a considerable cost savings.

About Yaral Pharma

Yaral Pharma Inc. (Parsippany, NJ) is the US generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, Yaral Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, Yaral Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaral-pharma.com or contact info@yaral-pharma.com or 866-218-9009.

About IBSA

IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

Contacts

Daina Basile

Kovak-Likly Communications

203-762-8833, dbasile@klcpr.com